Thrombolytic Science International

Thrombolytic Science International specializes in developing innovative biotherapeutics for treating ischemic strokes and heart attacks, focusing on enhancing thrombolytic therapy safety and effectiveness through a dual regimen approach. Thrombolytic Science International (TSci) is focused on creating transformative biotherapeutics for vascular emergencies. Founded by Alexis Wallace and Victor Gurewich, TSci is headquartered in Cambridge, US. The company raised USD 7.

5 mn in a funding round on January 12, 2012, aimed at advancing its innovative therapies. Thrombolytic Science, LLC (TSci) specializes in innovative biotherapeutics aimed at transforming the treatment landscape for ischemic strokes and heart attacks. The company’s core product is a dual thrombolytic regimen, which combines low doses of tissue plasminogen activator (tPA) and HisproUK, a novel compound designed to specifically target and dissolve degraded blood clots. This regimen is intended to enhance the speed and safety of thrombolytic therapy, allowing for administration in cases of suspected stroke or heart attack at the time of onset.

Currently, TSci's dual regimen has successfully completed a Phase 1 clinical study and is under evaluation in Phase 2 trials, focusing on patients with ischemic stroke. TSci aims to offer its solutions primarily in the United States, expanding its reach to markets such as Europe and possibly the Commonwealth of Independent States, where urgent vascular care is critical. Thrombolytic Science, LLC operates under a business model that emphasizes strategic collaborations and partnerships with healthcare providers, hospitals, and clinical research organizations. Revenue generation is rooted in the commercialization of its innovative thrombolytic therapy once regulatory approvals are secured, facilitating direct sales and potentially licensing agreements with pharmaceutical distributors.

TSci's flagship products include the low-dose dual therapy regimen for ischemic strokes and its patented HisproUK compound. The company is positioned to engage in B2B transactions, where hospitals and healthcare institutions would procure these therapies for use in emergency medical settings. As the company advances through clinical trials and moves towards market entry, the structure of its transactions is expected to align with healthcare procurement practices, focusing on the provision of efficacious, safer treatment options to address acute vascular events. Thrombolytic Science International is focused on advancing its dual thrombolytic regimen through ongoing Phase 2 trials, aiming for regulatory approvals that could lead to market entry.

The company intends to expand its presence into European markets and the Commonwealth of Independent States by 2024. The funding of USD 7. 5 mn raised in January 2012 will be utilized to support these clinical trials and facilitate the launch of its products, ensuring that innovative treatment options become available in critical healthcare settings.